^
    8d
    KEYNOTE 597: Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) (clinicaltrials.gov)
    P1/2, N=12, Terminated, Atara Biotherapeutics | Phase classification: P1b/2 --> P1/2
    Phase classification
    |
    Keytruda (pembrolizumab) • Tab-cel (tabelecleucel)
    10d
    ROSALIE: First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma (clinicaltrials.gov)
    P1/2, N=100, Completed, Enterome | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Mar 2024 | Trial primary completion date: Dec 2024 --> Jan 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • EO2401
    10d
    Spencer: A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (clinicaltrials.gov)
    P1/2, N=70, Terminated, Enterome | Active, not recruiting --> Terminated; Strategic decision
    Trial termination • Combination therapy • Checkpoint block • Metastases
    |
    Opdivo (nivolumab) • EO2401
    15d
    Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P3, N=158, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
    |
    FLT3 mutation • FLT3 wild-type
    |
    cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    25d
    Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma (clinicaltrials.gov)
    P1, N=18, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    olvimulogene nanivacirepvec (GL-ONC1)
    27d
    Self-Tumor Antigens in Solid Tumors Turned into Vaccines by α-gal Micelle Immunotherapy. (PubMed, Pharmaceutics)
    It is suggested that, in addition to converting treated metastases into an autologous TA vaccine, this treatment should be considered as a neoadjuvant therapy, administering α-gal micelles into primary tumors immediately following their detection. Such an immunotherapy will convert tumors into a personalized anti-TA vaccine for the period prior to their resection.
    Review • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    alpha-gal glycolipids (AGI-134)
    1m
    INO 5401 Vaccination in BRCA1/2 Mutation Carriers (clinicaltrials.gov)
    P1, N=44, Recruiting, University of Pennsylvania | Phase classification: P1b --> P1
    Phase classification
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    INO-5401 • rocakinogene sifuplasmid (INO-9012)
    2ms
    ALLELE: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (clinicaltrials.gov)
    P3, N=66, Recruiting, Atara Biotherapeutics | Trial primary completion date: Jun 2022 --> Aug 2025
    Trial primary completion date • Post-transplantation
    |
    Rituxan (rituximab) • Tab-cel (tabelecleucel)
    2ms
    16-1080.cc: Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=26, Completed, University of Colorado, Denver | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Vesanoid (tretinoin)
    2ms
    DECIST: Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=43, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    DOC1021
    2ms
    Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) (clinicaltrials.gov)
    P2, N=142, Recruiting, Genelux Corporation | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • docetaxel • albumin-bound paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • olvimulogene nanivacirepvec (GL-ONC1)
    2ms
    HSV G207 with a Single Radiation Dose in Children with Recurrent High-Grade Glioma (clinicaltrials.gov)
    P2, N=40, Recruiting, Pediatric Brain Tumor Consortium | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HSV G207
    2ms
    Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications. (PubMed, Br J Haematol)
    All cases were successfully managed with hydroxyurea...In conclusion, APL patients undergoing ATRA-ATO therapy with lower fibrinogen levels and platelet counts at diagnosis and with a massive bone marrow blast infiltrate should be carefully monitored for the development of leucocytosis during induction. DS and other treatment-related complications seem to occur almost exclusively in patients developing leucocytosis, who should necessarily receive DS prophylaxis and more intensive monitoring and supportive therapy to prevent treatment complications.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT expression
    |
    Vesanoid (tretinoin) • arsenic trioxide • hydroxyurea
    3ms
    A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (clinicaltrials.gov)
    P1, N=62, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Immunomodulating
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    cyclophosphamide • CAN-3110
    3ms
    Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, China Medical University Hospital | Recruiting --> Active, not recruiting | N=20 --> 10
    Enrollment closed • Enrollment change
    |
    Opdivo (nivolumab) • Vesanoid (tretinoin)
    3ms
    Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8+ T cells and inhibited tumor growth. (PubMed, J Immunother Cancer)
    Our data demonstrates the potential of activating TNFRSF25 by Abs and multimeric TL1A proteins for cancer immunotherapy and provides insights into their development astherapeutics.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD40 (CD40 Molecule)
    4ms
    MELODY-1: A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Microbiotica Ltd
    New P1 trial • Combination therapy
    |
    Keytruda (pembrolizumab)
    4ms
    Impaired Proliferation of CD8+ T Cells Stimulated with Monocyte-Derived Dendritic Cells Previously Matured with Thapsigargin-Stimulated LAD2 Human Mast Cells. (PubMed, J Immunol Res)
    Furthermore, these differences were comparably recapitulated in the ability of the tested DCs to induce IFNγ- and IFNγ/TNFα-producing T cells. These findings show a novel mechanism of MC-mediated regulation of adaptive immune responses.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
    4ms
    KEYNOTE-D88: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=209, Recruiting, NextCure, Inc. | N=131 --> 209
    Enrollment change • Checkpoint inhibition • Metastases
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • NC410
    5ms
    Spencer: A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (clinicaltrials.gov)
    P1/2, N=70, Active, not recruiting, Enterome | Trial completion date: Nov 2025 --> Oct 2024
    Trial completion date • Combination therapy • Checkpoint block • Metastases
    |
    Opdivo (nivolumab) • EO2401
    5ms
    HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Gregory K. Friedman, MD | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    HSV G207
    5ms
    IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study) (clinicaltrials.gov)
    P2, N=110, Terminated, Imcyse SA | Trial completion date: Jan 2025 --> May 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Jan 2024; No efficacy at primary analysis after 1 year. Long term follow-up stopped
    Trial completion date • Trial termination • Trial primary completion date
    5ms
    Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) (clinicaltrials.gov)
    P2, N=142, Not yet recruiting, Genelux Corporation
    New P2 trial • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • docetaxel • albumin-bound paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • olvimulogene nanivacirepvec (GL-ONC1)
    6ms
    Targeting IGF2-IGF1R Signaling to Reprogram the Tumor Microenvironment for Enhanced Viro-Immunotherapy. (PubMed, Neuro Oncol)
    This is the first study reporting that oHSV-induced secreted IGF2 exerts a critical role in resistance to oHSV therapy, which can be overcome by oHSV-D11mt as a promising therapeutic advance for enhanced viro-immunotherapy.
    Journal • Oncolytic virus • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IGF2 (Insulin-like growth factor 2)
    |
    CAN-3110
    6ms
    KEYNOTE-D14: To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (clinicaltrials.gov)
    P1/2, N=645, Recruiting, Amunix, a Sanofi Company | Trial primary completion date: Dec 2026 --> Aug 2027
    Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • VIR-5818
    6ms
    STARPAC2: A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer (clinicaltrials.gov)
    P2, N=170, Active, not recruiting, Queen Mary University of London | Not yet recruiting --> Active, not recruiting | Phase classification: P2b --> P2 | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: Feb 2024 --> Nov 2024
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Stroma
    |
    gemcitabine • albumin-bound paclitaxel • Vesanoid (tretinoin)
    6ms
    LySATRA: Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer (clinicaltrials.gov)
    P1/2, N=58, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris
    New P1/2 trial • Metastases
    |
    Vesanoid (tretinoin)
    6ms
    INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P1/2, N=52, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    temozolomide • Libtayo (cemiplimab-rwlc) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
    6ms
    Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis (clinicaltrials.gov)
    P1, N=128, Active, not recruiting, Xencor, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    7ms
    Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 (clinicaltrials.gov)
    P1, N=144, Recruiting, Vir Biotechnology, Inc. | Trial completion date: Mar 2024 --> Apr 2027 | Trial primary completion date: Sep 2023 --> Sep 2026
    Trial completion date • Trial primary completion date • Combination therapy
    7ms
    Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration. (PubMed, Mol Carcinog)
    In patients with incurable HPV16+ solid tumors treated with SQZ-PBMC-HPV, an increase in CD8+ T cell density within the tumor parenchyma was associated with superior disease control rate and overall survival. The product composition for patients with increased CD8+ T cell density was enriched for T cells.
    P1 data • Journal
    |
    CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • GZMB (Granzyme B)
    |
    HLA-A*02
    |
    SQZ-PBMC-HPV
    7ms
    INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov)
    P1/2, N=35, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
    7ms
    SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. (clinicaltrials.gov)
    P2, N=124, Recruiting, Vir Biotechnology, Inc. | Trial completion date: Oct 2026 --> Aug 2029 | Trial primary completion date: Oct 2026 --> Aug 2029
    Trial completion date • Trial primary completion date • Combination therapy
    7ms
    Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076) (clinicaltrials.gov)
    P3, N=186, Recruiting, Genelux Corporation | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial primary completion date
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • olvimulogene nanivacirepvec (GL-ONC1)
    8ms
    Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) (clinicaltrials.gov)
    P1/2, N=6, Terminated, Eureka Therapeutics Inc. | N=12 --> 6 | Trial completion date: Jun 2026 --> Jun 2023 | Recruiting --> Terminated | Trial primary completion date: Apr 2024 --> Jun 2023; Directing efforts to the pediatric study (ARYA-2) for this product
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    AFP (Alpha-fetoprotein)
    |
    ET140203
    8ms
    Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) (GlobeNewswire)
    P2/3 | N=700 | NCT05141721 | Sponsor: Gritstone bio, Inc. | "Gritstone bio...announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE...in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC)....Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a high-risk group, where clinical data are more mature ([95% CI, 0.15-1.38]; 44% censored); >90% of high-risk patients have liver metastases....GRANITE was generally well-tolerated with manageable adverse events; no patients have discontinued GRANITE due to adverse events....Mature PFS data expected in the third quarter of 2024; overall survival data expected in 1H 2025."
    P2 data
    |
    GRANITE
    8ms
    Melanoma extracellular vesicles inhibit tumor growth and metastasis by stimulating CD8 T cells. (PubMed, Mol Immunol)
    In vitro experiments showed that melanoma EV stimulates dendritic cells (DCs) maturation, and mature dendritic cells induce T lymphocyte activation. Thus, tumor cell-derived EVs can generate anti-tumor immunity in a prophylactic setting and may be potential candidates for cell-free tumor vaccines.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    8ms
    Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION] (clinicaltrials.gov)
    P2, N=15, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting
    Enrollment open
    8ms
    HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Gregory K. Friedman, MD | Recruiting --> Active, not recruiting | N=15 --> 24
    Enrollment closed • Enrollment change
    |
    HSV G207
    8ms
    SIDNEY: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Enterome | Trial primary completion date: Sep 2024 --> Jun 2025
    Trial primary completion date • Combination therapy
    |
    Rituxan (rituximab) • lenalidomide • EO2463
    8ms
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Dwight Owen | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    9ms
    KEYNOTE-D14: To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (clinicaltrials.gov)
    P1/2, N=645, Recruiting, Amunix, a Sanofi Company | Trial completion date: Dec 2026 --> Aug 2027
    Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • VIR-5818